CDKN2A/p16INK4a Rabbit Polyclonal Antibody (ER2001-30)

UNIPROT #

P42771

PROTEIN NAME

CDKN2A/p16INK4a

SYNONYMS

CCM2 antibody;CDK4 inhibitor p16 INK4 antibody;CDK4I antibody;CDKN2 antibody;CDKN2A antibody;Cell cycle negative regulator beta antibody;CMM2 antibody;Cyclin dependent kinase 4 inhibitor A antibody;Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) antibody;Cyclin Dependent Kinase Inhibitor 2A antibody;Cyclin dependent kinase inhibitor 2A isoform 4 antibody;Cyclin dependent kinase inhibitor 2A isoforms 1/2/3 antibody;Cyclin dependent kinase inhibitor p16 antibody;INK4 antibody;INK4A antibody;MLM antibody;MTS1 antibody;Multiple tumor suppressor 1 antibody;p14 antibody;p16 antibody;P16INK4 antibody;p16INK4a antibody;p19 antibody;p19Arf antibody;TP16 antibody

SUBCELLULAR LOCATION

Cytoplasm, Nucleus.

FUNCTION

CDKN2A, also known as cyclin-dependent kinase inhibitor 2A, is a gene which in humans is located at chromosome 9, band p21.3. It is ubiquitously expressed in many tissues and cell types.The gene codes for two proteins, including the INK4 family member p16 (or p16INK4a) and p14arf. Both act as tumor suppressors by regulating the cell cycle. p16 inhibits cyclin dependent kinases 4 and 6 (CDK4 and CDK6) and thereby activates the retinoblastoma (Rb) family of proteins, which block traversal from G1 to S-phase. p14ARF (known as p19ARF in the mouse) activates the p53 tumor suppressor. Somatic mutations of CDKN2A are common in the majority of human cancers, with estimates that CDKN2A is the second most commonly inactivated gene in cancer after p53. Germline mutations of CDKN2A are associated with familial melanoma, glioblastoma and pancreatic cancer.The CDKN2A gene also contains one of 27 SNPs associated with increased risk of coronary artery disease.